Bristol Myers lifts sales outlook as newer drugs drive growth

Bristol Myers Squibb (BMY) raised its 2026 revenue forecast to $49.75B-$50.25B, up from $50B, after Q3 results beat expectations. Non-GAAP EPS guidance updated to $6.35-$6.55. Q3 revenue rose 7.2% YoY to $13.1B, with Growth Portfolio sales up 12% to $7.7B, driven by newer drugs like Opdivo Qvantig.

Original reporting
Published Oct 29, 2026, 11:28 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 12:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Bristol Myers lifts sales outlook as newer drugs drive growth — source image
Decision brief

The 30-second read

$BMYBullishHigh
01

Why it matters

The guidance raise signals management confidence in newer oncology growth (notably Opdivo Qvantig) and provides fresh 2026 revenue and EPS ranges that can drive re-rating.

02

Market read

Fresh 2026 guidance and product-level growth details create a direct catalyst for BMY positioning versus patent-expiration concerns.

03

What to watch

The article cites acquired in-process R&D and licensing income in EPS guidance; traders may want to separate underlying operating momentum from one-time or non-core items.

Relevance 9/10Novelty 9/10Timing: today, following the company’s Q3 results and guidance update

Background

Bristol Myers is shifting mix toward newer medicines to mitigate revenue pressure as blockbuster Eliquis approaches patent expiration.

Company-level read

Ticker impact

$BMYBullishHigh confidence
Context

Bristol Myers raised its 2026 revenue forecast and updated non-GAAP EPS guidance after Q3 results beat expectations, led by Opdivo Qvantig growth.

Expected impact

Likely upward bias as the market reprices 2026 growth durability from newer drugs versus looming Eliquis generic pressure.

Evidence & confidence

The article provides specific, company-issued forecast ranges for revenue and non-GAAP EPS, plus product-level growth (Opdivo Qvantig and Growth Portfolio) that explains the upgrade.

Market effects

Reinforces the oncology large-cap narrative that newer formulations can offset patent-loss risk, potentially supporting peer sentiment around pipeline execution.

Limited direct regional spillover; primarily a US pharma earnings and guidance read-through.

Modest global relevance, as the driver is company-specific oncology product performance and US patent-timing risk.

Counterpoint

The upgrade may be partially offset by accelerating Eliquis generic competition risk, so upside could fade if newer-drug growth does not scale enough to fully replace legacy declines.

Key entities

  • Bristol Myers Squibb

    US-listed drugmaker raising 2026 revenue and non-GAAP EPS guidance after Q3 beat, led by newer oncology medicines.

  • Opdivo Qvantig

    Injectable alternative cited as a key growth driver, with quarterly sales reported at $334M.

  • Eliquis

    Blockbuster anticoagulant flagged for potential US generic competition in 2028, a key medium-term risk.

Related articles

$BMYMed

Deucravacitinib Linked to Arthritis Improvements in SLE

Deucravacitinib, a drug developed by Bristol Myers Squibb, showed improvements in arthritis symptoms for 60% of SLE patients with active joints in a 48-week study. Patients taking 3 mg twice daily had higher odds of joint count reductions compared to placebo. The study was published in Lupus Science & Medicine.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$OMCLow

Omnicom Media Retains Bristol Myers Squibb Account

Omnicom Media retained Bristol Myers Squibb's US media account, adding healthcare professional media responsibilities. The account had been handled by IPG Mediabrands, acquired by Omnicom. Bristol Myers Squibb's 2023 media budget was $430 million. This follows Omnicom's win of Novo Nordisk's US media buying business from WPP.

$EVOMedAI 8/10

Evotec and Bristol Myers Squibb Advance Strategic Protein Degradation Partnership with Second IND Acceptance

Evotec (EVO) and Bristol Myers Squibb received FDA clearance for a second Investigational New Drug (IND) in their protein degradation partnership. The first candidate entered Phase 1 trials in March 2026, and the second is expected to start in 2027. The collaboration leverages Evotec's drug discovery capabilities and Bristol Myers Squibb's CELMoD agent library to develop molecular glue degraders for oncology and other therapeutic areas.